Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
CLA Antitrust and Consumer Protection Section In-House Counsel Summit
Speaking Engagement
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
Axinn Receives Multiple LCLD Awards; Announces 2026 Fellows and Pathfinders
Workplace Culture & Opportunity
Axinn Secures Multiple Shortlists for 2026 Global Competition Review Awards
Awards & Recognitions
Antitrust
DOJ’s First Antitrust Whistleblower Payout Signals a New Enforcement Playbook
Axinn Viewpoints
Antitrust
First Whistleblower Reward Sparks Race to Report, Lawyers Say
Media Mentions
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
